Rockwell MedicalSTU:RWM 26 1-Year ROIIC % is 161.51 as of Mar. 2026. GuruFocus rates STU:RWM with a GF Score™ of 26/100 and a GF Value™ of €0.82 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 964 Drug Manufacturers companies, Rockwell Medical ranks better than 91.49% on this metric.
1-Year Return on Invested Incremental Capital (1-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 1-year.
Rockwell Medical's 1-Year ROIIC % for the quarter that ended in Mar. 2026 was 161.51%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Rockwell Medical's 1-Year ROIIC % or its related term are showing as below:
STU:RWM's 1-Year ROIIC % is ranked better than 91.49% of 964
companies
in the Drug Manufacturers industry
Industry Median: 1.315
vs STU:RWM: 161.51
Rockwell Medical (STU:RWM) 1-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Rockwell Medical 1-Year ROIIC % Related Terms
Rockwell Medical 1-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Rockwell Medical's 1-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:RWM vs CPHI, TXMD, MRMD: 1-Year ROIIC % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Rockwell Medical's 1-Year ROIIC %, along with its competitors' market caps and 1-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rockwell Medical 1-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Rockwell Medical's 1-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Rockwell Medical's 1-Year ROIIC % falls into.
Rockwell Medical's 1-Year ROIIC % for the quarter that ended in Mar. 2026 is calculated as:
1-Year ROIIC %
=
1-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
1-Year Incremental Invested Capital
=
( -4.14 (Mar. 2026) - 0.468 (Mar. 2025) )
/
( 24.523 (Mar. 2026) - 29.307 (Mar. 2025) )
=
-4.608
/
-4.784
=
96.32%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** TTM data of NOPAT and Invested Capital was used to calculate 1-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Rockwell Medical (STU:RWM) has a 1-Year ROIIC % of 161.51 as of Mar. 2026. 1-Year ROIIC % measures the change in earnings as a percentage of change in investment over 1-year. View historical data on Rockwell Medical and its competitors. According to the industry distribution chart, Rockwell Medical ranks #82 out of 964 companies in the Drug Manufacturers industry, placing it in the top 8.5%.
Is Rockwell Medical's 1-Year ROIIC % too high?
Rockwell Medical's current 1-Year ROIIC % is 161.51. The Drug Manufacturers industry median 1-Year ROIIC % is 1.32. Rockwell Medical's value of 161.51 is 12182.1% above this industry median. Based on the distribution chart, Rockwell Medical ranks #82 out of 964 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Rockwell Medical has a GF Score™ of 26/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Rockwell Medical's 1-Year ROIIC % compare to CPHI and TXMD?
According to the Drug Manufacturers industry distribution chart, Rockwell Medical ranks #82 out of 964 companies for 1-Year ROIIC %. This places Rockwell Medical in the top 9% of its industry — outperforming the majority of peers. The industry median 1-Year ROIIC % is 1.32. Rockwell Medical's value of 161.51 is 12182.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year ROIIC % for a Drug Manufacturers company?
The median 1-Year ROIIC % among Drug Manufacturers companies is 1.32, based on 964 companies in the industry. Companies in the top quartile (top 25%) have a 1-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 1-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rockwell Medical's current 1-Year ROIIC % of 161.51 is 12182.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year ROIIC % mean?
A high 1-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 1-Year ROIIC % measures the change in earnings as a percentage of change in investment over 1-year. View historical data on Rockwell Medical and its competitors. For the Drug Manufacturers industry, the median 1-Year ROIIC % is 1.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rockwell Medical's current 1-Year ROIIC % is 161.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rockwell Medical stock overvalued right now?
Based on GuruFocus' analysis, Rockwell Medical (STU:RWM) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.82, compared to a current price of €4.80 — trading 485.4% above its estimated fair value. The current 1-Year ROIIC % is 161.51 and 12182.1% above the Drug Manufacturers industry median of 1.32. Rockwell Medical's overall GF Score™ is 26/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year ROIIC % calculated?
1-Year ROIIC % is calculated from a company's financial statements. For Rockwell Medical (STU:RWM), the current 1-Year ROIIC % is 161.51 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rockwell Medical (STU:RWM) Overvalued in 2026?
Based on GuruFocus' analysis, Rockwell Medical stock appears to be overvalued.
The current stock price of €4.80 is trading 485.4% above its estimated GF Value™ of €0.82.
GuruFocus considers Rockwell Medical to be Significantly Overvalued.
Key valuation signals for STU:RWM:
1-Year ROIIC %: 161.51
GF Value™: €0.82 vs. price of €4.80 (485.4% above fair value)
Industry Position: 12182.1% above the Drug Manufacturers median (#82 of 964)
No single metric tells the full story. See the STU:RWM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rockwell Medical Inc is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers. It is a supplier of liquid bicarbonate concentrates, acid, and dry bicarbonate concentrates for dialysis patients in the United States. The company's products include CitraPure citric acid concentrate, RenalPure liquid acid concentrate, and SteriLyte bicarbonate concentrate, among others. The company delivers the majority of its hemodialysis concentrates products and mixers to dialysis clinics throughout the United States and internationally, utilizing its own delivery trucks and third-party carriers.
26GF Score
Get the complete analysis for STU:RWM
1-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:RWM has been successfully added to your 
